NEOS Investment Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

NEOS Investment Management’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-8,767	Closed	-$408K	–	599
2025 Q4	$408K	Sell	8,767 -13,533	-61%	-$602K	﹤0.01%	622
2025 Q3	$929K	Sell	22,300 -35,801	-62%	-$1.14M	0.01%	529
2025 Q2	$1.67M	Sell	58,101 -706	-1%	-$21.8K	0.02%	402
2025 Q1	$1.97M	Buy	58,807 +874	+2%	+$32.6K	0.04%	326
2024 Q4	$2.96M	Buy	57,933 +544	+0.9%	+$30.4K	0.07%	236
2024 Q3	$2.93M	Buy	57,389 +3,819	+7%	+$197K	0.09%	205
2024 Q2	$2.4M	Buy	53,570 +13,121	+32%	+$606K	0.1%	184
2024 Q1	$1.89M	Buy	40,449 +26,968	+200%	+$1.06M	0.12%	162
2023 Q4	$480K	Buy	+13,481	New	+$413K	0.05%	291

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

NEOS Investment Management's CRNX Position: Q1 2026 in Review

NEOS Investment Management sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2026, closing a stake of 8,767 shares — an estimated $408K sold.

NEOS Investment Management first reported a position in CRNX in Q4 2023 and held it in 9 quarters. The position peaked at $2.96M in Q4 2024. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

NEOS Investment Management reported no remaining Crinetics Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
NEOS Investment Management sold 8,767 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $408K.
NEOS Investment Management first reported a position in Crinetics Pharmaceuticals in Q4 2023 and held it in 9 quarters.
NEOS Investment Management's Crinetics Pharmaceuticals position peaked at $2.96M in Q4 2024.
243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on NEOS Investment Management's 13F filing for Q1 2026, filed 15 May 2026.